Enzymatic Casein Peptide Preparation for Brain Function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic drugs for Alzheimer's disease, such as acetylcholinesterase inhibitors, have limitations including liver toxicity, strong side effects, and high costs, and existing peptides that improve amnesia require high doses or invasive administration methods, lacking efficacy as an orally ingestable substance.
Innovation Solution
A method for enzymatically preparing peptides from milk casein using proteases to produce hydrolysates with specific amino acid sequences, which are then used in food or pharmaceutical compositions to improve brain function and prevent amnesia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If acetylcholinesterase inhibitors such as donepezil hydrochloride are used to treat Alzheimer's disease, then the function of cholinergic nerve is improved by increasing acetylcholine level, but liver toxicity and strong side effects occur making long-term administration impossible
Solution Approach 1:
The patent replaces expensive, toxic pharmaceutical drugs with a safe, naturally-derived peptide that can be administered orally without liver toxicity. The peptide acts as a short-lived but safe alternative that achieves therapeutic effect without the harmful cumulative effects of conventional drugs
Solution Approach 2:
The invention changes the chemical structure from conventional acetylcholinesterase inhibitors to a specific peptide sequence (SEQ ID NO: 1) that acts through a different mechanism (C3a receptor-mediated acetylcholine release) while achieving the same therapeutic goal of improving cholinergic function without toxicity
2Reliability
If existing peptides such as XPLPR are administered to improve amnesia, then scopolamine-induced amnesia is improved through acetylcholine release, but large doses or invasive administration routes are required reducing practical applicability
Solution Approach 1:
The patent modifies the peptide structure from XPLPR to the specific sequence SEQ ID NO: 1, which changes the mechanism of action to be more efficient at lower doses. This structural parameter change enables oral administration at practical doses while maintaining the amnesia-improving effect through C3a receptor-mediated acetylcholine release
Solution Approach 2:
The invention creates a peptide that can be administered orally in practical doses without requiring invasive routes, making it suitable for long-term treatment of amnesia conditions. The peptide provides therapeutic effect through a safe, non-invasive route that is convenient for regular administration
3Reliability
If conventional therapeutic drugs are used for Alzheimer's disease, then cholinergic nerve function is improved, but the treatment is expensive and cannot be administered for long periods
Solution Approach 1:
The patent replaces expensive conventional drugs with a peptide that can be produced through enzymatic hydrolysis of casein, a abundant and inexpensive protein source. This makes the treatment more affordable and suitable for long-term administration without the cost constraints of pharmaceutical drugs
Solution Approach 2:
The invention changes the therapeutic approach from expensive synthetic acetylcholinesterase inhibitors to a naturally-derived peptide that acts through C3a receptor-mediated mechanisms, achieving brain function improvement through a more cost-effective and sustainable pathway
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method efficiently produces peptides with brain function-improving actions, demonstrated by preventing scopolamine-induced amnesia in animal models, offering a safer and more effective alternative to existing treatments.
Implementation Method 1
hydrolyzing milk casein with an enzymatic catalyst comprising a protease to prepare a hydrolysate
Data Source
AI summary
The invention provides a method for preparing a peptide for improving brain function, comprising hydrolyzing milk casein with an enzymatic catalyst comprising a protease to produce a hydrolysate comprising: (i) a peptide consisting of the amino acid sequence shown in SEQ ID NO: 1 or a variant thereof; (ii) a peptide consisting of the amino acid sequence shown in SEQ ID NO: 2 or a variant thereof; or (iii) a mixture of the peptides of (i) and (ii), wherein the production yield of each of the peptides is 2% or more, or the total production yield of the mixture is 10% or more. The invention also provides a food or drink or a pharmaceutical composition containing the hydrolysate.